<DOC>
	<DOC>NCT00796991</DOC>
	<brief_summary>The purpose of this clinical research study is to learn the pharmacokinetics of Ipilimumab when combined with Paclitaxel/Carboplatin or Dacarbazine</brief_summary>
	<brief_title>Drug-Drug Interaction - 3 Arm - Carboplatin/Paclitaxel, Dacarbazine</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Histologic diagnosis of advanced malignant melanoma Eastern Cooperative Oncology Group (ECOG) performances status 01 Measurable/evaluable disease as per modified World Health Organization (mWHO) criteria Evidence of active brain metastases Prior treatment with anticytotoxic lymphocyte antigen 4 (CTLA4) or antiCD137 (type of tumor necrosis factor) antibody Total Bilirubin greater than (&gt;) 1.5 * upper limit of normal (ULN) and aspartate aminotransferase (AST) or alanine aminotransferase (ALT) &gt; 2.5 * upper limit of normal (ULN) Prior Autoimmune disease Use of immunosuppressing therapies</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Untreated Advanced Melanoma</keyword>
</DOC>